AZD7442

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

COVID-19Corona Virus Infection

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

1

AZD7442

AstraZeneca

Phase 3

72

COVID-19 Vaccine

Moderna

Preclinical

273

Angiomax

BBaxter Healthcare Corporation

Preclinical

24

Aquasol E

NNational Eye Institute (NEI)

Preclinical

15

Benadryl

PParkedale

Preclinical

16

SARS-COV-2 VACCINE

Moderna

Preclinical

27

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—8

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

19

Standard Preparation

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Preclinical

110

Moderna COVID-19 Vaccine

Moderna

Preclinical

4Show 10 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-197 trials

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults

Completed·AstraZeneca·Phase 3·NCT04625972·1,131 enrolled

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

Completed·AstraZeneca·Phase 3·NCT04625725·5,197 enrolled

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT05780437·1,455 enrolled

Show 4 more trials

ACTIV-3: Therapeutics for Inpatients With COVID-19

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT04501978·2,753 enrolled

ACTIV-2: A Study for Outpatients With COVID-19

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2/3·NCT04518410·4,044 enrolled

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19

Terminated·AstraZeneca·Phase 2·NCT05375760·251 enrolled

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults

Completed·AstraZeneca·Phase 3·NCT04723394·910 enrolled

Adult2 trials

A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults

Completed·AstraZeneca·Phase 1·NCT05437289·61 enrolled

Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Completed·AstraZeneca·Phase 1·NCT05166421·224 enrolled

Pediatrics1 trial

AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics

Completed·AstraZeneca·Phase 1·NCT05281601·46 enrolled

Corona Virus Infection1 trial

Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults

Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 3·NCT04315948·1,552 enrolled

Details

Drug Info

Related News